Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A recent study tested the effectiveness and tolerability of Technivie (ombitasvir/paritaprevir/ritonavir) among those over 65.
This was among a small group of people who contracted the virus within one year, most of whom had HIV as well.
With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?
The triple-drug regimen comes in a once-daily single tablet.
FDA warns of risk of hepatitis B virus reactivation in patients coinfected with hepatitis C virus and hepatitis B virus.
The FDA has required AbbVie to add warnings to two of its HCV treatments after receiving reports of serious liver damage.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.